[go: up one dir, main page]

CN109248314A - A kind of preparation method of pig blue-ear disease inactivated vaccine - Google Patents

A kind of preparation method of pig blue-ear disease inactivated vaccine Download PDF

Info

Publication number
CN109248314A
CN109248314A CN201811162675.0A CN201811162675A CN109248314A CN 109248314 A CN109248314 A CN 109248314A CN 201811162675 A CN201811162675 A CN 201811162675A CN 109248314 A CN109248314 A CN 109248314A
Authority
CN
China
Prior art keywords
marc
porcine
preparation
chinese medicine
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201811162675.0A
Other languages
Chinese (zh)
Inventor
徐高骁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanning Institute
Original Assignee
Nanning Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanning Institute filed Critical Nanning Institute
Priority to CN201811162675.0A priority Critical patent/CN109248314A/en
Publication of CN109248314A publication Critical patent/CN109248314A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0684Cells of the urinary tract or kidneys
    • C12N5/0686Kidney cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/70Undefined extracts
    • C12N2500/76Undefined extracts from plants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/10011Arteriviridae
    • C12N2770/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/10011Arteriviridae
    • C12N2770/10051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明属于养殖技术领域,尤其是一种猪蓝耳病灭活疫苗的制备方法,包括以下步骤:(1)在MEM基础培养基中加入新生牛血清、中药提取液配制成培养液;(2)使用培养液对Marc‑145细胞进行驯化培养,得到Marc‑145细胞培养液;(3)将猪蓝耳病毒液解入到Marc‑145细胞培养液培养得到病毒液;(4)将病毒液进行澄清、分离、浓缩、纯化;(5)将纯化的病毒液灭活后,与中药提取液配置成灭活疫苗。本发明所使用的中药提取液由茯苓、蒲公英、黄芪、艾草、玉米须、菟丝子、白术、刺五加、淫羊藿制成,能提T细胞、B细胞等细胞因子的活性,促进机体产生抗体。因此,本发明使用中药提取液驯化培养Marc‑145细胞、配置灭活疫苗,能有效提高灭活疫苗对免疫系统的刺激性。The invention belongs to the technical field of breeding, in particular to a preparation method of an inactivated porcine blue-ear disease vaccine, comprising the following steps: (1) adding newborn bovine serum and traditional Chinese medicine extract to a MEM basal medium to prepare a culture solution; (2) The Marc-145 cells are domesticated and cultured using the culture medium to obtain the Marc-145 cell culture fluid; (3) the porcine blue ear virus fluid is decomposed into the Marc-145 cell culture fluid and cultured to obtain the virus fluid; (4) the virus fluid is subjected to Clarify, separate, concentrate and purify; (5) After inactivating the purified virus liquid, configure it with the traditional Chinese medicine extract to form an inactivated vaccine. The traditional Chinese medicine extract used in the present invention is made of Poria cocos, dandelion, astragalus, wormwood, corn silk, dodder, Atractylodes, Acanthopanax senticosus, Epimedium produce antibodies. Therefore, the present invention uses the traditional Chinese medicine extract to domesticate and cultivate Marc-145 cells, and configures the inactivated vaccine, which can effectively improve the stimulation of the inactivated vaccine to the immune system.

Description

A kind of preparation method of pig blue-ear disease inactivated vaccine
Technical field
The invention belongs to cultural technique field, especially a kind of preparation method of pig blue-ear disease inactivated vaccine.
Background technique
Pig blue-ear disease (PRRS), also known as mystery swine disease, new swine disease, pig Epidemic abortion and breathing syndrome, pig reproduction With breathing syndrome, blue otopathy, swine fever epidemic disease etc., it is most important a kind of immunosuppressive disease in China's swine disease, mainly causes to be pregnant Sow Late term abortions, premature labor produce stillborn foetus and the mummification of fetus and increase, there is respiratory symptom in piglet and Preweaning death rate increase with And the immunization machine obstacle of Adult Pig.PRRS virus (PRRSV) belongs to shell type virales, Arteriviridae, is in oval, There is cyst membrane, genome is single strand plus RNA virus;The Principle Target of the virus is Monocyte-macrophages system, at present The primary duplication position for generally believing the virus is the macrophage in schneiderian membrance or upper respiratory tract system, is then followed by blood Ring diffuses to other organs, and is proliferated in mononuclear phagocyte system wherein.
Pig blue-ear disease is a kind of highly contagious disease, and the pig of various kinds, all ages and classes and purposes can infect, but Piglet most easy infection with pregnant sow and within 1 monthly age.Illness pig and with malicious pig be this disease the important infection sources, main propagation Approach is that contact infection, air borne and sperm are propagated, and can also pass through placenta vertical transmission.
Currently, the main means of prevention of pig blue-ear disease is vaccine inoculation, but in practice process, blue-ear disease vaccine is anti- It controls and often will appear immuning failure, the main reason is that it is longer that body generates the neutralizing antibody time, or cannot produce when vaccine immunity The antibody of raw high-titer, and it is possible to infection pig blue-ear disease poison during this period.
Summary of the invention
In order to solve the above technical problems existing in the prior art, the present invention provides a kind of pig blue-ear disease inactivated vaccines Preparation method, particular by following technical scheme realize:
A kind of preparation method of pig blue-ear disease inactivated vaccine, comprising the following steps:
(1) preparation of culture solution: newborn bovine serum is added in MEM basal medium, Chinese medicine extract is configured to cultivate Liquid A and culture solution B;
(2) cell culture: after Marc-145 cell recovery, being linked into culture solution A and cultivated, thin to Marc-145 After born of the same parents grow up to single layer;Continue from selecting pollution-free, morphologically normal Marc-145 cell to be linked into culture solution B in cell monolayer Culture, to get Marc-145 cell culture fluid when cell grows to the 75%~80% of culture solution surface;
(3) Virus culture: pig blue-ear disease venom is linked into Marc-145 cell culture fluid, continue culture to 85% with After there is CPE in upper cell, harvest culture virus liquid;
(4) purify: the virus liquid of harvest is clarified using hollow fiber column, micro-filtration, it is 80-100 times dense after, using dividing Sub- sieve chromatography column purifies filtrate;
(5) inactivate: after the virus liquid using beta-propiolactone inactivation purifying, the Chinese medicine extract mixing for being added 5% or so is matched It is set to inactivated vaccine.
Preferably, the culture solution A is newborn bovine serum and the 15-20% that 10% is added in MEM basal medium Chinese medicine extract.
Preferably, the culture solution B is newborn bovine serum and the 35-45% that 10% is added in MEM basal medium Chinese medicine extract.
Preferably, the Chinese medicine extract is by weight by 10-15 parts of Poria cocos, 6-10 portions of dandelions, 6-10 parts of Huangs Stilbene, 3-5 part wormwood, 10-15 parts of corn stigmas, 3-5 portions of Semen Cuscutaes, 2-4 parts of Rhizoma Atractylodis Macrocephalaes, 2-4 parts of wilsoniis, 2-4 parts of Herba Epimedii.
Preferably, Poria cocos, dandelion, Radix Astragali, Chinese mugwort the preparation of the Chinese medicine extract: are weighed respectively by weight ratio Grass, corn stigma, Semen Cuscutae, Rhizoma Atractylodis Macrocephalae, wilsonii, Herba Epimedii, and crush respectively, then it is mixed and made into medicinal powder;8 are added into medicinal powder After times water impregnates 20-30min, heating decocts 1-1.5h, and filtering obtains filtrate A and the dregs of a decoction;5 times of 80% second is added into the dregs of a decoction Alcohol is heated to 60-70 DEG C, keeps constant temperature 30-40min, and filtering recycles ethyl alcohol, obtains liquor B;Filtrate A and liquor B are mixed Afterwards, the filtering with microporous membrane for the use of aperture being 0.5-10 μm sterilizes to get Chinese medicine extract.
Preferably, the preparation of the pig blue-ear disease venom: 1 monthly age piglet dissect of pig blue-ear disease will be suffered from, acquires lung Dirty and serum is configured to suspension with MEM basal medium after homogenate grinding, adds dual anti-processing, and 1500rmp is centrifuged 20min, takes Supernatant is through 0.20 μm of miillpore filter degerming to get pig blue-ear disease venom.
Preferably, the step (2), cultivation temperature are 36-37 DEG C.
Preferably, the cell density of the Marc-145 cell culture fluid is 6 × 105/ ml~8 × 105/ml
Preferably, the step (3), the access amount of pig indigo plant virus liquid are the 1- of Marc-145 cell culture fluid volume 1.5%.
The beneficial effects of the present invention are: by Poria cocos, dandelion, Radix Astragali, wormwood, corn stigma, Semen Cuscutae, Rhizoma Atractylodis Macrocephalae, thorn five Add, the Chinese medicine extract of Herba Epimedii preparation can promote the generations of the cell factors such as T cell, B cell, monocytes/macrophages, improve The activity of cell factor promotes the generation of antibody;Marc-145 cell is carried out using the culture medium containing Chinese medicine extract tame and docile Change culture, Marc-145 cell can absorb the ingredient in Chinese medicine extract during the growth process, the Marc- after reusing domestication 145 cell culture pig blue-ear disease poison, pig blue-ear disease poison also can promote antibody raw from part traditional Chinese medicine ingredients are wherein absorbed to have The ability of production;Inactivated vaccine is prepared using the pig blue-ear disease venom after Chinese medicine extract and inactivation, further improves inactivation epidemic disease Irritation of the seedling to cell factor.The preparation method of indigo plant otopathy inactivated vaccine provided by the invention, use can promote body to generate The Chinese medicine extract domestication Marc-145 cell of antibody prepares the pig blue-ear disease venom after inactivation, and inactivated vaccine obtained can pierce Swash body and generate antibody, solve inactivated vaccine it is immune when body generate that the neutralizing antibody time is longer, cannot generate high-titer The problem of antibody, has improved inactivated vaccine to the irritation of immune system.
Specific embodiment
It is limited below with reference to specific embodiment technical solution of the present invention is further, but claimed Range is not only limited to made description.
1 Chinese medicine extract of embodiment
Component: 10g Poria cocos, 6g dandelion, 6g Radix Astragali, 3g wormwood, 10g corn stigma, 3g Semen Cuscutae, 2g Rhizoma Atractylodis Macrocephalae, 2g thorn five Add, 2g Herba Epimedii.
Preparation method: Poria cocos, dandelion, Radix Astragali, wormwood, corn stigma, Semen Cuscutae, white is weighed respectively by weight ratio Art, wilsonii, Herba Epimedii, and crush respectively, then it is mixed and made into medicinal powder;After 8 times of water immersion 20min are added into medicinal powder, add Heat decocts 1h, and filtering obtains filtrate A and the dregs of a decoction;5 times of 80% ethyl alcohol is added into the dregs of a decoction, is heated to 60-70 DEG C, keeps constant temperature 30min, filtering recycle ethyl alcohol, obtain liquor B;After filtrate A and liquor B are mixed, filtered using the micropore that aperture is 0.5-10 μm Film filtering, sterilizing obtain Chinese medicine extract 1.
2 Chinese medicine extract of embodiment
Component: 12g Poria cocos, 8g dandelion, 8g Radix Astragali, 4g wormwood, 12g corn stigma, 4g Semen Cuscutae, 3g Rhizoma Atractylodis Macrocephalae, 3g thorn five Add, 3g Herba Epimedii.
Preparation method: Poria cocos, dandelion, Radix Astragali, wormwood, corn stigma, Semen Cuscutae, white is weighed respectively by weight ratio Art, wilsonii, Herba Epimedii, and crush respectively, then it is mixed and made into medicinal powder;After 8 times of water immersion 25min are added into medicinal powder, add Heat decocts 1.2h, and filtering obtains filtrate A and the dregs of a decoction;5 times of 80% ethyl alcohol is added into the dregs of a decoction, is heated to 60-70 DEG C, keeps permanent Warm 35min, filtering recycle ethyl alcohol, obtain liquor B;After filtrate A and liquor B are mixed, the micropore for the use of aperture being 0.5-10 μm Membrane filtration, sterilizing, obtains Chinese medicine extract 2.
3 Chinese medicine extract of embodiment
Component: 15g Poria cocos, 10g dandelion, 10g Radix Astragali, 5g wormwood, 15g corn stigma, 5g Semen Cuscutae, 4g Rhizoma Atractylodis Macrocephalae, 4g thorn Slender acanthopanax, 4g Herba Epimedii.
Preparation method: Poria cocos, dandelion, Radix Astragali, wormwood, corn stigma, Semen Cuscutae, white is weighed respectively by weight ratio Art, wilsonii, Herba Epimedii, and crush respectively, then it is mixed and made into medicinal powder;After 8 times of water immersion 30min are added into medicinal powder, add Heat decocts 1.5h, and filtering obtains filtrate A and the dregs of a decoction;5 times of 80% ethyl alcohol is added into the dregs of a decoction, is heated to 60-70 DEG C, keeps permanent Warm 40min, filtering recycle ethyl alcohol, obtain liquor B;After filtrate A and liquor B are mixed, the micropore for the use of aperture being 0.5-10 μm Membrane filtration, sterilizing, obtains Chinese medicine extract 3.
4 pig blue-ear disease venom of embodiment
1 monthly age piglet dissect of pig blue-ear disease will be suffered from, acquires lungs and serum, cultivated after homogenate grinding with the basis MEM Basigamy is set to suspension, adds dual anti-processing, and 1500rmp is centrifuged 20min, takes supernatant through 0.20 μm of miillpore filter degerming, i.e., Obtain pig blue-ear disease venom.
The preparation of 5 inactivated vaccine of embodiment
Preparation method, comprising the following steps:
(1) preparation of culture solution: 10% newborn bovine serum is added in MEM basal medium, 20% Chinese medicine extract 1 is matched Culture solution A is made, 10% newborn bovine serum is added in MEM basal medium, 45% Chinese medicine extract 1 is configured to culture solution B;
(2) it cell culture: after Marc-145 cell recovery, is linked into culture solution A and is trained in 36-37 DEG C of greenhouse It supports, after Marc-145 cell grows up to single layer;Pollution-free, morphologically normal Marc-145 cell is selected to access from cell monolayer Continue to cultivate in 36-37 DEG C of greenhouse into culture solution B, to get thin when cell grows to the 75%~80% of culture solution surface Born of the same parents' density is 6 × 105/ ml~8 × 105The Marc-145 cell culture fluid of/ml;
(3) Virus culture: pig blue-ear disease venom is linked into Marc-145 cell culture fluid, continue culture to 85% with After there is CPE in upper cell, harvest culture virus liquid;Wherein the access amount of pig indigo plant virus liquid is Marc-145 cell culture fluid volume 1%;
(4) purify: the virus liquid of harvest is clarified using hollow fiber column, micro-filtration, it is 100 times dense after, using molecule Sieve chromatography column purifies filtrate;
(5) inactivate: after the virus liquid using beta-propiolactone inactivation purifying, the Chinese medicine extract mixing for being added 5% or so is matched It is set to inactivated vaccine.
6 inactivated vaccine of embodiment
Preparation method, comprising the following steps:
(1) preparation of culture solution: 10% newborn bovine serum is added in MEM basal medium, 18% Chinese medicine extract 2 is matched Culture solution A is made, 10% newborn bovine serum is added in MEM basal medium, 40% Chinese medicine extract 2 is configured to culture solution B;
(2) it cell culture: after Marc-145 cell recovery, is linked into culture solution A and is trained in 36-37 DEG C of greenhouse It supports, after Marc-145 cell grows up to single layer;Pollution-free, morphologically normal Marc-145 cell is selected to access from cell monolayer Continue to cultivate in 36-37 DEG C of greenhouse into culture solution B, when cell grows to the 75%~80% of culture solution surface, obtains cell Density is 6 × 105/ ml~8 × 105The Marc-145 cell culture fluid of/ml;
(3) Virus culture: pig blue-ear disease venom is linked into Marc-145 cell culture fluid, continue culture to 85% with After there is CPE in upper cell, harvest culture virus liquid;Wherein, the access amount of pig indigo plant virus liquid is Marc-145 cell culture liquid Long-pending 1.2%.
(4) purify: the virus liquid of harvest is clarified using hollow fiber column, micro-filtration, it is 90 times dense after, using molecular sieve Chromatographic column purifies filtrate;
(5) inactivate: after the virus liquid using beta-propiolactone inactivation purifying, the Chinese medicine extract mixing for being added 5% or so is matched It is set to inactivated vaccine.
7 inactivated vaccine of embodiment
Preparation method, comprising the following steps:
(1) preparation of culture solution: 10% newborn bovine serum is added in MEM basal medium, 15% Chinese medicine extract 3 is matched Culture solution A is made, 10% newborn bovine serum is added in MEM basal medium, 35% Chinese medicine extract 3 is configured to culture solution B;
(2) cell culture: after Marc-145 cell recovery, being linked into culture solution A and cultivated in 36-37 DEG C, After Marc-145 cell grows up to single layer;Pollution-free, morphologically normal Marc-145 cell is selected to be linked into from cell monolayer Continue to cultivate in 36-37 DEG C of greenhouse in culture solution B, when cell grows to the 75%~80% of culture solution surface, obtains cell Density is 6 × 105/ ml~8 × 105The Marc-145 cell culture fluid of/ml;
(3) Virus culture: pig blue-ear disease venom is linked into Marc-145 cell culture fluid, continue culture to 85% with After there is CPE in upper cell, harvest culture virus liquid;Wherein, the access amount of pig indigo plant virus liquid is Marc-145 cell culture liquid Long-pending 1.5%.
(4) purify: the virus liquid of harvest is clarified using hollow fiber column, micro-filtration, it is 80 times dense after, using molecular sieve Chromatographic column purifies filtrate;
(5) inactivate: after the virus liquid using beta-propiolactone inactivation purifying, the Chinese medicine extract mixing for being added 5% or so is matched It is set to inactivated vaccine.
1 safety testing of test example
Test method: 20 10 age in days Kunming suckling mouses are bought back, suckling mouse is randomly divided into 4 groups, every group after same raising 10 days 5;Wherein it is inoculated with inactivated vaccine prepared by embodiment 6-7 respectively for 3 groups, another set is inoculated with commercially available pig indigo plant ear inactivated vaccine; Every suckling mouse intramuscular injection 0.1mL vaccine is observed 2 weeks, if second of the suckling mouse intramuscular injection 5mL vaccine of situation without exception every, Continue observation 2 weeks, dissect.
Test result: 4 groups of suckling mouses vaccinate for the first time, are no different paradoxical reaction in 2 weeks;4 groups of suckling mouses inject epidemic disease for the second time Seedling does not occur abnormal response in 2 weeks, does not also occur unusual condition through dissect, illustrate inactivated vaccine prepared by the present invention and city Inactivated vaccine is sold to suckling mouse safety.
2 potency test of test example
Test method: 20 30 age in days piglets are randomly divided into 4 groups, every group 5;1 embodiment 5- is immunized in 1-3 group respectively The inactivated vaccine (5ml/) of 7 preparations, 4 groups are immunized 1 commercially available pig blue-ear disease inactivated vaccine (5ml/);After immune the 5th, 15, blood sample 30,50,70,90, is acquired respectively, uses the antibody of PRRS virus ELISA antibody assay kit detection serum Level, the results are shown in Table 1:
The PRRSV antibody situation (A of 1 piglet of table650nm)
5 days 15 days 30 days 50 days 70 days 90 days
1 group 0.98±0.16 1.43±0.38 1.83±0.42 1.23±0.36 0.78±0.27 0.60±0.20
2 groups 0.92±0.13 1.48±0.32 1.96±0.40 1.37±0.57 0.89±0.31 0.64±0.23
3 groups 1.03±0.21 1.52±0.37 1.81±0.38 1.28±0.31 0.91±0.35 0.71±0.18
4 groups 0.98±0.17 1.26±0.31 0.43±0.35 1.71±0.47 1.23±0.28 0.83±0.21
As seen from the table, the piglet of 1-3 group reaches peak value in 30 days or so antibody levels, and 4 groups of piglet was at 50 days or so Antibody level reaches peak value, illustrates that inactivated vaccine prepared by the present invention compared with commercially available pig blue-ear disease inactivated vaccine, can stimulate son The immune response of pig, makes it generate lot of antibodies in a relatively short period of time, can rapidly play a role.
It is important to point out that, above embodiments and test example are only limitted to do further technical solution of the present invention herein Elaboration and understanding, should not be understood as it is further to technical solution of the present invention limited, what those skilled in the art made The innovation and creation of non-protruding essential characteristics and marked improvement still fall within protection category of the invention.

Claims (9)

1.一种猪蓝耳病灭活疫苗的制备方法,包括以下步骤:1. a preparation method of porcine PRRS inactivated vaccine, comprising the following steps: (1)培养液的配制:在MEM基础培养基中加入新生牛血清、中药提取液配制成培养液A和培养液B;(1) Preparation of culture solution: add newborn bovine serum and Chinese medicine extract to MEM basal medium to prepare culture solution A and culture solution B; (2)细胞培养:将Marc-145细胞复苏后,接入到培养液A中进行培养,待Marc-145细胞长成单层后;从单层细胞中选择无污染、形态正常的Marc-145细胞接入到培养液B中继续培养,待细胞长到培养液表面的75%~80%时,即得Marc-145细胞培养液;(2) Cell culture: After the Marc-145 cells are recovered, they are inserted into the medium A for culture, and after the Marc-145 cells grow into a monolayer; the Marc-145 cells with no pollution and normal morphology are selected from the monolayer cells. The cells are inserted into the culture medium B to continue culturing, and when the cells grow to 75% to 80% of the surface of the culture medium, the Marc-145 cell culture medium is obtained; (3)病毒培养:将猪蓝耳病毒液接入到Marc-145细胞培养液中,继续培养至85%以上细胞出现CPE后,收获培养病毒液;(3) Virus culture: insert the porcine blue ear virus liquid into the Marc-145 cell culture medium, continue to culture until more than 85% of the cells appear CPE, and then harvest the cultured virus liquid; (4)纯化:将收获的病毒液采用中空纤维柱进行澄清、微滤、浓,80-100倍后,采用分子筛层析柱对滤液进行纯化;(4) Purification: the harvested virus liquid is clarified, microfiltered and concentrated by a hollow fiber column, and after 80-100 times, the filtrate is purified by a molecular sieve chromatography column; (5)灭活:采用β-丙内酯灭活纯化的病毒液后,加入5%左右的中药提取液混合配置成灭活疫苗。(5) Inactivation: after using β-propiolactone to inactivate the purified virus liquid, add about 5% of the traditional Chinese medicine extract and mix it to prepare an inactivated vaccine. 2.如权利要求1所述的猪蓝耳病灭活疫苗的制备方法,其特征在于,所述的培养液A是在MEM基础培养基中加入10%的新生牛血清和15-20%的中药提取液。2. the preparation method of porcine PRRS inactivated vaccine as claimed in claim 1, is characterized in that, described nutrient solution A is to add 10% newborn bovine serum and 15-20% serum in MEM basal medium Chinese herbal extract. 3.如权利要求1所述的猪蓝耳病灭活疫苗的制备方法,其特征在于,所述的培养液B是在MEM基础培养基中加入10%的新生牛血清和35-45%的中药提取液。3. the preparation method of porcine PRRS inactivated vaccine as claimed in claim 1, is characterized in that, described nutrient solution B is to add 10% newborn bovine serum and 35-45% serum in MEM basal medium Chinese herbal extract. 4.如权利要求1所述的猪蓝耳病灭活疫苗的制备方法,其特征在于,所述的中药提取液按重量份计由10-15份茯苓、6-10份蒲公英、6-10份黄芪、3-5份艾草、10-15份玉米须、3-5份菟丝子、2-4份白术、2-4份刺五加、2-4份淫羊藿。4. the preparation method of porcine PRRS inactivated vaccine as claimed in claim 1 is characterized in that, described Chinese medicine extract is composed of 10-15 parts of Poria, 6-10 parts of dandelion, 6-10 parts by weight Astragalus, 3-5 parts of wormwood, 10-15 parts of corn silk, 3-5 parts of dodder, 2-4 parts of Atractylodes, 2-4 parts of Acanthopanax senticosus, 2-4 parts of Epimedium. 5.如权利要求4所述的猪蓝耳病疫苗的制备方法,其特征在于,所述的中药提取液的制备:按重量份配比分别称取茯苓、蒲公英、黄芪、艾草、玉米须、菟丝子、白术、刺五加、淫羊藿,并分别粉碎,然后混合制成药粉;向药粉中加入8倍水浸泡20-30min后,加热煎煮1-1.5h,过滤,得到滤液A和药渣;向药渣中加入5倍80%乙醇,加热到60-70℃,保持恒温30-40min,过滤,回收乙醇,得到滤液B;将滤液A和滤液B混合后,使用孔径为0.5-10μm的微孔滤膜过滤,灭菌,即得中药提取液。5. the preparation method of porcine PRRS vaccine as claimed in claim 4, is characterized in that, the preparation of described Chinese medicine extract: take Poria, dandelion, astragalus, wormwood, corn silk by weight respectively , Dodder, Atractylodes, Acanthopanax senticosus, Epimedium, and pulverized respectively, and then mixed to make medicinal powder; after adding 8 times of water to the medicinal powder, soaked for 20-30min, heated and boiled for 1-1.5h, filtered to obtain filtrate A and medicinal residues; add 5 times of 80% ethanol to the medicinal residues, heat to 60-70°C, keep constant temperature for 30-40min, filter, recover ethanol, and obtain filtrate B; after mixing filtrate A and filtrate B, use a pore size of 0.5- Filter through a 10 μm microporous membrane and sterilize to obtain the Chinese medicine extract. 6.如权利要求1所述的猪蓝耳病灭活疫苗的制备方法,其特征在于,所述的猪蓝耳病毒液的制备:将患有猪蓝耳病的1月龄仔猪剖检,采集肺脏及血清,匀浆研磨后用MEM基础培养基配置成悬浮液,加双抗处理,1500rmp离心20min,取上清液经0.20μm的微孔滤膜除菌,即得猪蓝耳病毒液。6. the preparation method of porcine PRRS inactivated vaccine as claimed in claim 1, is characterized in that, the preparation of described porcine blue-ear virus liquid: necropsy of 1-month-old piglets suffering from porcine PRRS, Lungs and serum were collected, homogenized and ground into a suspension with MEM basal medium, treated with double antibodies, centrifuged at 1500 rmp for 20 min, and the supernatant was sterilized by a 0.20 μm microporous filter to obtain a porcine blue ear virus solution. . 7.如权利要求1所述的猪蓝耳病灭活疫苗的制备方法,其特征在于,所述的步骤(2),培养温度为36-37℃。7 . The method for preparing an inactivated porcine PRRS vaccine according to claim 1 , wherein in the step (2), the culture temperature is 36-37° C. 8 . 8.如权利要求1所述的猪蓝耳病灭活疫苗的制备方法,其特征在于,所述的Marc-145细胞培养液的细胞密度为6×105/ml~8×105/ml。8 . The method for preparing an inactivated porcine PRRS vaccine according to claim 1 , wherein the cell density of the Marc-145 cell culture solution is 6×10 5 /ml~8×10 5 /ml. 9 . . 9.如权利要求1所述的猪蓝耳病灭活疫苗的制备方法,其特征在于,所述的步骤(3),猪蓝病毒液的接入量为Marc-145细胞培养液体积的1-1.5%。9. the preparation method of porcine blue ear inactivated vaccine as claimed in claim 1, is characterized in that, described step (3), the access amount of porcine blue virus liquid is 1 % of Marc-145 cell culture liquid volume -1.5%.
CN201811162675.0A 2018-09-30 2018-09-30 A kind of preparation method of pig blue-ear disease inactivated vaccine Withdrawn CN109248314A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811162675.0A CN109248314A (en) 2018-09-30 2018-09-30 A kind of preparation method of pig blue-ear disease inactivated vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811162675.0A CN109248314A (en) 2018-09-30 2018-09-30 A kind of preparation method of pig blue-ear disease inactivated vaccine

Publications (1)

Publication Number Publication Date
CN109248314A true CN109248314A (en) 2019-01-22

Family

ID=65045393

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811162675.0A Withdrawn CN109248314A (en) 2018-09-30 2018-09-30 A kind of preparation method of pig blue-ear disease inactivated vaccine

Country Status (1)

Country Link
CN (1) CN109248314A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917332A (en) * 2022-04-28 2022-08-19 兆丰华生物科技(福州)有限公司 Combined immunization method of porcine reproductive and respiratory syndrome inactivated vaccine and rabbit-derived classical swine fever live vaccine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101422500A (en) * 2008-12-12 2009-05-06 湖南农业大学 Immunoenhancement regulator of pig blue-ear disease vaccine and use thereof
US20110020464A1 (en) * 2009-07-27 2011-01-27 Ushijima Richard N Methods of treatment using thymus-derived compositions
CN103495166A (en) * 2013-09-18 2014-01-08 浙江美保龙生物技术有限公司 Preparation method of complex live vaccine for porcine reproductive and respiratory syndrome
CN103495162A (en) * 2013-09-18 2014-01-08 浙江美保龙生物技术有限公司 Preparation method of porcine reproductive and respiratory syndrome compound inactivated vaccine
CN104798727A (en) * 2015-04-30 2015-07-29 河南民正农牧股份有限公司 Traditional Chinese medicine composition capable of keeping whole antibody level of porcine reproductive and respiratory syndrome and introduction method
CN105213918A (en) * 2015-09-23 2016-01-06 青岛华仁技术孵化器有限公司 The immune formulation of control Porcine reproductive and respiratory syndrome
CN106237323A (en) * 2016-09-22 2016-12-21 齐鲁动物保健品有限公司 Pig blue-ear disease purified vaccine and preparation method thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101422500A (en) * 2008-12-12 2009-05-06 湖南农业大学 Immunoenhancement regulator of pig blue-ear disease vaccine and use thereof
US20110020464A1 (en) * 2009-07-27 2011-01-27 Ushijima Richard N Methods of treatment using thymus-derived compositions
CN103495166A (en) * 2013-09-18 2014-01-08 浙江美保龙生物技术有限公司 Preparation method of complex live vaccine for porcine reproductive and respiratory syndrome
CN103495162A (en) * 2013-09-18 2014-01-08 浙江美保龙生物技术有限公司 Preparation method of porcine reproductive and respiratory syndrome compound inactivated vaccine
CN104798727A (en) * 2015-04-30 2015-07-29 河南民正农牧股份有限公司 Traditional Chinese medicine composition capable of keeping whole antibody level of porcine reproductive and respiratory syndrome and introduction method
CN105213918A (en) * 2015-09-23 2016-01-06 青岛华仁技术孵化器有限公司 The immune formulation of control Porcine reproductive and respiratory syndrome
CN106237323A (en) * 2016-09-22 2016-12-21 齐鲁动物保健品有限公司 Pig blue-ear disease purified vaccine and preparation method thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ZHAN YONG WEI ET AL.,: "Inhibitory effects of indigowoad root polysaccharides on porcine reproductive and respiratory syndrome virus replication in vitro", 《ANTIVIR THER》 *
中华传统医药简明读本编委会: "《中华传统医药简明读本 神奇的艾灸美颜术》", 30 June 2016, 广西科学技术出版社 *
兰新财等: "增免康(芪贞增免颗粒)增强仔猪免疫功能的试验研究", 《浙江畜牧兽医》 *
李朝龙: "《中医流体学理论与实践:疑难病"清补运"通用治则临床验证》", 31 December 2016, 羊城晚报出版社 *
葛闻华等: "《别把乙肝当成病》", 28 February 2003, 华南理工大学出版社 *
陈轶玉等: "《病原生物学与免疫学》", 31 July 2018, 江苏凤凰科学技术出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917332A (en) * 2022-04-28 2022-08-19 兆丰华生物科技(福州)有限公司 Combined immunization method of porcine reproductive and respiratory syndrome inactivated vaccine and rabbit-derived classical swine fever live vaccine

Similar Documents

Publication Publication Date Title
CA2127991A1 (en) Preparation of antigens of and of vaccines for the virus of mystery disease, antigens and vaccines obtained for the prevention of this disease
CN107513524A (en) One plant of pig Sai Neijia paddy virus stain and its application
CN107184969A (en) A kind of A types Sai Nika paddy viral inactivation vaccines and its preparation method and application
CN103585626B (en) Preparation method for newcastle disease and infectious bursal disease bigeminal composite inactivated vaccine
CN107201334A (en) Can be suspended the bovine kidney cells cultivated and its suspension culture method and application
CN101716341B (en) Human diploid cell inactivated rabies vaccine and preparation method thereof
CN103495166A (en) Preparation method of complex live vaccine for porcine reproductive and respiratory syndrome
CN110373379A (en) A kind of method that the full suspension cell of Marc-145 directly cultivates PRRS virus vaccine
CN101524536B (en) Japanese encephalitis vaccine prepared by human embryonic lung fibroblasts and preparation method thereof
CN101376878B (en) Pig propagation and breathing syndrome virus stain, and inactivated vaccine prepared thereby
CN106237323A (en) Pig blue-ear disease purified vaccine and preparation method thereof
CN104043117A (en) Vaccine composition, preparation method and application thereof
CN109248314A (en) A kind of preparation method of pig blue-ear disease inactivated vaccine
CN101234198A (en) Method of preparing pig replication and respiration syndrome deactivation concentrated vaccine 'SD1 strain'
CN103495162B (en) Preparation method of porcine reproductive and respiratory syndrome compound inactivated vaccine
Nuttall et al. Isolation of a coronavirus during studies on puffinosis, a disease of the Manx shearwater (Puffinus puffinus)
CN106367398B (en) A kind of human Coxsackievirus A group 16 virus strain and its application in the preparation of inactivated vaccine
CN101380470B (en) Pig parvovirus live vaccine
CN102973932A (en) Trivalent inactivated vaccine of porcine reproductive and respiratory syndrome virus, porcine circovirus type 2, and porcine pseudorabies virus and preparation method thereof
CN104474542A (en) Preparation method of bi-combined inactivated vaccine
CN102363770A (en) Recombinant Baculovirus and Its Subunit Vaccine Fusion Expressing Porcine Circovirus Type 2 Cap Protein and Somatostatin
CN102160892A (en) Epidemic encephalitis B and enterovirus 71 (EV71) combined vaccine
CN110241089A (en) A kind of method of full suspension cell culture production porcine reproductive and respiratory syndrome virus antigen
CN104388399B (en) PRRSV attenuated strain which is capable of inducing pig body to relatively early generate interferon and neutralizing antibody and possesses wide-spectrum immunogenicity
CN111686246B (en) Antigen-antibody complex vaccine for porcine epidemic diarrhea virus and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20190122